Home
Search
Study Topics
Glossary
|
|
|
|
|
|
Sponsored by: |
Merck KGaA |
---|---|
Information provided by: | EMD Pharmaceuticals |
ClinicalTrials.gov Identifier: | NCT00148798 |
The purpose of this trial is to investigate the efficacy of cetuximab in combination with chemotherapy in comparison to chemotherapy alone in patients with advanced non small cell lung cancer who did not received prior chemotherapy. Overall survival will be taken as primary measure of efficacy.
Condition | Intervention | Phase |
---|---|---|
Non Small Cell Lung Cancer |
Drug: cetuximab + cisplatin + vinorelbine Drug: cisplatin + vinorelbine |
Phase III |
Study Type: | Interventional |
Study Design: | Treatment, Randomized, Open Label, Active Control, Parallel Assignment, Efficacy Study |
Official Title: | Open, Randomized, Controlled, Multicenter Phase III Study Comparing Cisplatin/Vinorelbine Plus Cetuximab Versus Cisplatin/Vinorelbine as First-Line Treatment for Patients With EGFR-Expressing Advanced NSCLC. |
Enrollment: | 1125 |
Study Start Date: | November 2004 |
Study Completion Date: | July 2007 |
Arms | Assigned Interventions |
---|---|
1: Experimental |
Drug: cetuximab + cisplatin + vinorelbine
cetuximab given as an i.v. infusion every week (400mg/m2 initial dose and 250mg/m2 subsequent doses) until PD + cisplatin 80mg/m2 i.v. infusion on day 1 of each 3-week cycle + vinorelbine 25mg/m2 i.v. infusion on days 1 and 8 of each 3-week cycle.
|
2: Active Comparator |
Drug: cisplatin + vinorelbine
cisplatin 80mg/m2 i.v. infusion on day 1 of each 3-week cycle + vinorelbine 25mg/m2 i.v. infusion on days 1 and 8 of each 3-week cycle.
|
Ages Eligible for Study: | 18 Years and older |
Genders Eligible for Study: | Both |
Accepts Healthy Volunteers: | No |
Inclusion Criteria:
Exclusion Criteria:
Principal Investigator: | Robert Pirker, Professor | Universitätsklinik für Innere Medizin I, Wien |
Responsible Party: | Merck KGaA ( Isil Montaner ) |
Study ID Numbers: | EMR 62202-046 |
Study First Received: | September 7, 2005 |
Last Updated: | December 13, 2007 |
ClinicalTrials.gov Identifier: | NCT00148798 |
Health Authority: | Austria: Federal Ministry for Health and Women |
Cetuximab Non small cell lung cancer Lung cancer |
Cisplatin/vinorelbine Monoclonal antibody Erbitux |
Thoracic Neoplasms Non-small cell lung cancer Cetuximab Vinblastine Carcinoma Antibodies, Monoclonal Antibodies Vinorelbine |
Respiratory Tract Diseases Cisplatin Lung Neoplasms Lung Diseases Carcinoma, Non-Small-Cell Lung Immunoglobulins Neoplasms, Glandular and Epithelial |
Respiratory Tract Neoplasms Neoplasms by Histologic Type Molecular Mechanisms of Pharmacological Action Antineoplastic Agents Physiological Effects of Drugs Mitosis Modulators Antimitotic Agents |
Pharmacologic Actions Neoplasms Neoplasms by Site Radiation-Sensitizing Agents Therapeutic Uses Tubulin Modulators Antineoplastic Agents, Phytogenic |